
|Videos|November 9, 2022
LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer
Author(s)Urology Times staff
“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.
Advertisement
Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA reports increased demand, supply efforts for estradiol transdermal patches
2
The UroOnc Minute: Perioperative Intravesical Chemotherapy at Nephroureterectomy, With Surena F. Matin, MD, FACS
3
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
4
NeoBLAST trial tests active surveillance after complete response in MIBC
5











